Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature by unknown
CASE REPORT Open Access
Reactivation of occult HBV infection in an
HIV/HCV Co-infected patient successfully
treated with sofosbuvir/ledipasvir: a case
report and review of the literature
Gabriele Fabbri*, Ilaria Mastrorosa, Alessandra Vergori, Valentina Mazzotta, Carmela Pinnetti, Susanna Grisetti,
Mauro Zaccarelli, Adriana Ammassari and Andrea Antinori
Abstract
Background: Reactivation of occult or inactive Hepatitis B virus (HBV) infection during immunosuppressant
treatments is well known and widely described in literature. The same observation has been made in Hepatitis C
(HCV)-infected patients previously exposed to HBV and treated with interferon-free DAA treatments. Because of
common transmission routes, persons may have been exposed to HCV, HBV and HIV, but few cases have been
reported in this scenario to date. Frequency of HBV reactivation in HIV/HCV co-infected patients previously exposed
to HBV and treated with DAA remains unclear. Herein, we report an episode of HBV reactivation in an HIV/HCV
co-infected patient prescribed with sofosbuvir/ledipasvir for HCV.
Case presentation: The patient is a Caucasian 54-years old female, with HIV/HCV co-infection (genotype 4), and a
previous exposure to HBV, documented by negativity of HBsAg and positivity of HBsAb and HBcAb. Her medical
history included: myocardial infarct, chronic kidney disease stage 3, chronic obstructive pulmonary disease, and mild
pulmonary hypertension. HCV had not been treated with interferon (IFN)-based regimens and liver stiffness was 10.
5 KPa (Metavir stage F3) at hepatic elastography. Because of CKD, she was prescribed with a nucleoside reverse
transcriptase (NRTI)-sparing regimen including darunavir/ritonavir plus etravirine, and thereafter with sofosbuvir/
ledipasvir for 12 weeks. Four weeks after DAA termination, the patient was hospitalized with symptoms of acute
hepatitis. Blood tests showed HCV RNA <12 IU/ml, but positivity of HBAg, HBeAg, and of anti-core antibodies (IgM
and IgG), while anti-HBs and anti-HBe antibodies were negative. HBV DNA was 6.06 Log10 IU/ml. Entecavir was
started obtaining resolution of symptoms, normalization of liver enzymes, as well as reduction of HBV DNA and of
quantitative HBV surface antigen.
Conclusions: This case-report highlights the risk of HBV reactivation with interferon-free DAA treatment in HIV/HCV
co-infected patients previously exposed to HBV and who have contraindications for treatment with nucleoside/
nucleotide reverse transcriptase Inhibitors because of comorbid conditions. In the setting of HIV infection, clinicians
prescribing DAA should be aware of this risk, and HBV assessment at treatment start as well as virological monitoring
during DAA treatment is recommended. Large epidemiological and virological studies are needed to investigate
reactivation of occult HBV infection more in depth.
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Background
Reactivation of HBV infection during immunosuppres-
sant treatments is well known and widely described in
literature [1]. The risk concerns subjects with occult
HBV infection (HBV DNA detected in serum or in the
liver in HBsAg-negative patients with or without serologic
markers of previous viral exposure) or inactive HBV
chronic carriers (HBsAg-positive with normal ALT and
HBV DNA <3.30 log10 IU/ml), either undergoing trans-
plant or treated with chemotherapy or immunosuppres-
sant drugs for hematologic malignancies or rheumatologic
disorders [2].
In the past, with the use of interferon (IFN)-based
HCV therapy, exacerbation of acute HBV hepatitis in
HBV-exposed patients has been described and an im-
mune modulating role of IFN postulated [3]. More re-
cently, a similar observation has been made with the
use of interferon-free directly acting antivirals (DAA)
for HCV treatment [4]. In HIV/HCV co-infected patients,
who show HCV cure rates comparable to the general
population [5], only very few cases of HBV reactivation
have been reported [6–10]. Thus, the frequency of HBV
reactivation in HIV/HCV co-infected patients previously
exposed to HBV and treated with DAA remains unclear.
Herein, we report an episode of reactivation of occult
HBV infection in an HIV/HCV co-infected patient pre-
scribed with sofosbuvir/ledipasvir for HCV treatment.
Further, a short review of similar cases published in litera-
ture is outlined.
Case presentation
The patient is a Caucasian 54-years old female diagnosed
with HIV in 1986 and with chronic HCV hepatitis (geno-
type 4) in 1992. For many years, she was lost to follow-up
and refused antiretroviral therapy presenting only once in
2011, when blood tests showed HIV RNA 4.93 log10 IU/
ml, CD4 cells 245/mmc. Concurrently, previous exposure
to HBV infection was documented: 12.2 mIU/ml HBsAb
(positive >10 mIU/ml), positive HBcAb, and negative
HBsAg at 0.01 IU/ml (positive >0.05 IU/ml). Afterwards
she showed up again in June 2015, when viroimmunologi-
cal exams showed: HIV RNA 5.28 log10 copies/ml and
CD4 count 218/mmc. At that time, her medical history in-
cluded: myocardial infarct, chronic kidney disease (CKD)
stage 3, chronic obstructive pulmonary disease, and mild
pulmonary hypertension. HCV had not been treated with
IFN-based regimens and liver stiffness was 10.5 KPa
(Metavir stage F3) at hepatic elastography. Because of
CKD, first-line antiretroviral treatment was a nucleoside
reverse transcriptase (NRTI)-sparing regimen including
darunavir/ritonavir 800/100 mg plus etravirine 400 mg
QD. In January 2016, blood tests showed HIV RNA not
detected <40 copies/ml with CD4 cells 283/mmc and
treatment with sofosbuvir/ledipasvir 400/90 mg once daily
was prescribed for 12 weeks. In May 2016, four weeks
after treatment completion, the patient presented with
jaundice reporting vomiting, nausea, and abdominal
pain. She was admitted to hospital, and an elevation of
liver enzymes (ALT 435 IU/l and AST 410 IU/l,
respectively) and total bilirubin at 7.1 mg/dl were docu-
mented. HCV RNA was <12 IU/ml, HIV RNA <40 cop-
ies/ml and CD4 count had increased to 561/mmc. With
regards to HBV markers, HBsAg (3.71 log10 IU/ml)
and HBeAg changed into positive together with IgM
and IgG HBcAb, while HBsAb and HBeAb remained
negative. Furthermore, HBV DNA was 6.06 log10 IU/ml.
Treatment with entecavir 0.5 mg once daily was promptly
started obtaining resolution of symptoms. One month
later, blood tests documented normalization of transami-
nases and reduction of HBV DNA at 3.78 log10 IU/l, of
HBsAg 1.91 log10 IU/ml and negativization of HBeAg
(Fig. 1). Treatment for HBV infection is still ongoing with-
out adverse events and sustained virological response for
HCV was achieved at 12 and at 24 weeks of observation.
Discussion
HBV reactivation of occult or inactive HBV infection in
HCV-infected persons during or after DAA therapy is
considered a rare event, even though lately an important
warning by the FDA about 24 cases of HBV reactivation
during DAA HCV treatment has been released [11]. In
literature to date, only six cases of these have been re-
ported and characteristics are summarized in Table 1: all
events occurred in subjects aged 50 years or more, mostly
infected by HCV genotype 1, with frequent previous IFN
exposure, and treated with sofobuvir- or daclatasvir-based
DAA regimens. Notably, only one case referred to a per-
son with HIV co-infection. Occasionally HBV reactivation
occurred during DAA treatment, while otherwise it devel-
oped after treatment completion. In some cases, diagnosis
was retrospectively established.
To date, risk of HBV reactivation during treatment
with ledipasvir/sofosbuvir seems low, and our patient is
only the second case described in literature [7]. Regard-
ing frequency of the event, reassuring data are available
from a recent study by Sulkowski et al., which retro-
spectively reanalyzed HBV markers in serum samples of
173 HCV-infected patients without active HBV or HIV
infection and treated with a combination of ledipasvir/
sofosbuvir. Notably, HBV reactivation during or after
HCV clearance was found in none out of the 103 previ-
ously HBV-exposed patients [12]. Differently, in patients
with HCV and HBV co-infection, transitory HBV DNA
reactivation rate seems very high, reaching 88% of a
small case series treated with ledipasvir/sofosbuvir [13].
Since accurate information regarding risk of HBV reacti-
vation in patients undergoing DAA therapy is lacking,
an important prospective study is ongoing in patients
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with active HBV/HCV infection [13], but the issue
should also be addressed in HCV-infected patients with
occult HBV infection.
In our patient, the rapid clearance of HCV RNA with
DAA treatment could have triggered HBV reactivation
leading to acute symptomatic hepatitis B. It also should
to be noted that, the low levels of HBsAb in 2011 and
the absence of this protective marker at hepatitis onset,
might have played an important role in allowing HBV
reactivation. In fact, our patient was not taking any ARV
regimen for 15 years after HIV diagnosis and this has
led to marked immunodeficiency: similarly to what hap-
pens in patients undergoing allogenic stem cells trans-
plantation, we can assume that she may have lost her
immunity against HBV [14].
The molecular mechanisms involved in HCV/HBV in-
terferences are controversial and incompletely under-
stood. It seems that HBV can be chronically suppressed
by HCV infection with alternate phases of dominance of
one virus on the other [15, 16] and a suppressing effect
of HCV core proteins on HBV replication has been
postulated in some studies [17, 18]. Other studies have
suggested that, host genes and immune regulation, such
as kinase pathways or microRNA pathways, mediate
the mechanism of underlying HBV inhibition [19, 20].
Regardless of the molecular mechanisms involved in
HCV/HBV co-infection, the introduction of DAA drugs
that are specifically directed against HCV without inhibi-
tory effect on HBV may unbalance viral and/or host inter-
actions and eventually allow HBV reactivation [21].
Our case report poses some further questions, because
the patient had HBV reactivation after DAA treatment,
but also was HIV-positive making the scenario even
more complex. On one side, HIV-infected patients may
experience various levels of immune deficiency, because
of lower CD4 cell count and immune dysregulation [22],
malignancies or rheumatologic diseases. Also immune
reconstitution in antiretroviral-treated patients may play
Fig. 1 Plasma HIV, HCV, HBV viral loads, liver function and CD4 cell count depicted over time
Table 1 Characteristics of patients with HBV reactivation during or after DAA treatment for HCV published in literature
Patient Ref. Gender, age HCV genotype Previous IFN DAA treatment HBV profile HIV status Symptoms onset
1 [7] M, 53 4d Yes SOF/LDV Resolved HBV + At 6 weeks during DAA
2 [6] M, 55 1a Yes SOF/SMV Inactive HBV - At 8 weeks during DAA
3 [6] M, 57 1a Yes SOF/SMV Occult HBV - At 4 weeks during DAA
4 [10] F, 59 1b Yes SOF/SMV/RBV Resolved HBV - At 11 weeks during DAA
5 [9] M, 69 1b No DCV/ASV Inactive HBV - At 6 weeks during DAA
6 [8] F, 83 1b NA DCV/ASV NA (HBsAg neg) - At 20 weeks after DAA
Legend: M male, F female, IFN interferon, RBV ribavirin, SOF sofosbuvir, SMV simeprevir, DCV daclatasvir, ASV asunaprevir, HBV hepatitis B virus, HCV hepatitis C
virus, DAA direct antiviral agents, NA not available, neg negative
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a role in the same direction. In fact, reactivation of
several latent infections, including HBV infection, is fa-
cilitated by immune reconstitution [23], and our patient
experienced a relevant increase in CD4 cell count when
comparing values before and after DAA treatment.
On the contrary however, it is likely that a consider-
able proportion of patients with HIV infection will re-
ceive anti-HBV agents, like lamivudine, emtricitabine
or tenofovir, as part of their antiretroviral therapy
during DAA therapy, and therefore will be protected
from HBV reactivation. Nonetheless, this may not
apply to a considerable number of HIV-positive pa-
tients, that have contraindications for treatment with
nucleoside/nucleotide reverse transcriptase Inhibitors
because of comorbid conditions and who receive dual
regimens [24].
Conclusions
In conclusion, this case-report highlights the risk of HBV
reactivation with interferon-free DAA treatment in HIV/
HCV co-infected patients previously exposed to HBV and
who have contraindications for treatment with nucleo-
side/nucleotide reverse transcriptase Inhibitors because of
comorbid conditions. In the setting of HIV infection, clini-
cians prescribing DAA should be aware of this risk, and
HBV assessment at treatment start as well as virological
monitoring during DAA treatment is recommended.
Large epidemiological and virological studies are needed
to investigate reactivation of occult HBV infection more
in depth.
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